Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Triple‑negative breast cancer (TNBC) accounts for 10‑15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …

Treatment of triple-negative breast cancer (TNBC) remains challenging. Deciphering the
orchestration of metabolic pathways in regulating ferroptosis will provide new insights into …

Triple-negative breast cancer (TNBC) is a collection of biologically diverse cancers
characterized by distinct transcriptional patterns, biology, and immune composition. TNBCs …

Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer,
negatively expresses estrogen receptor, progesterone receptor, and the human epidermal …

The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway
which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian …

As the field of translational 'omics has progressed, refined classifiers at both genomic and
proteomic levels have emerged to decipher the heterogeneity of breast cancer in a clinically …

Triple-negative breast cancer (TNBC) shows a higher response rate to systemic therapy
compared with other breast cancer subtypes. However, the tumor differentiation of TNBC is …

Breast cancer is the most commonly occurring cancer in women. There were over two-
million new cases in world in 2018. It is the second leading cause of death from cancer in …

Among different types of breast cancers (BC), triple-negative BC (TNBC) amounts to 15% to
20% of breast malignancies. Three principal characteristics of TNBC cells are (i) extreme …